( ) has seen a significant drop in short interest during the month of April. On April 15, there were 5,620,000 shorted shares, which is a decrease of 21,4% from the total of 7,150,000 on March 31st. The days-tocover ratio, based on an average daily share volume of 2,480,000, is currently 2.3 days. About 0.2% of shares are short-sold.
Takeda Pharmaceutical stock performance
During Friday's trading hours, the stock fell $0.27 to $16.59. The company's stock changed hands 2,957,367 times, as opposed to the average of 2,431,018. The company has a $52.50 billion market capitalization, a P/E ratio of 25,14 and a Beta of 0.63. The company's debt-to equity ratio is 0.63. Its current ratio is 1.16, and its quick ratio 0.75. Takeda Pharmaceutical's twelve-month low is $12.28, and its twelve-month high is $17.15. The company released its last quarterly results on Thursday 2nd February. The company reported $0.46 per share for the quarter. For the quarter, revenue was $8.40 billion. Takeda Pharmaceutical's return on equity was 12.43 % and its net margin was 6.84%. Takeda Pharmaceutical is expected to post 2.1 earnings for the current fiscal year, according to analysts.
Takeda Pharmaceuticals Institutional Trading
Recently, hedge funds and institutional investors changed their holdings in the company. Point72 Asset Management bought shares of Takeda Pharmaceutical in the 4th Quarter valued at approximately $43,410,000. Arrowstreet Capital Limited Partnership increased its stake in Takeda Pharmaceutical shares by 171.3% during the fourth quarter. Arrowstreet Capital Limited Partnership owns 3,904,296 of the company stock, worth $60,000,000 after purchasing an additional 2,465,178 during the last quarter. Millennium Management LLC increased its stake in Takeda Pharmaceutical shares by 124.1% during the fourth quarter. Millennium Management LLC owns 2,238,381 of the company stock, worth $34,919,000. This is after purchasing an additional 1,239 382 shares in the last quarter. More Investments Ltd purchased a new stake in Takeda Pharmaceutical shares in the fourth quarter valued at $16,489,000. Investors own 2.05% the stock of Takeda Pharmaceutical.
Wall Street analysts forecast growth
Several research analysts have recently published reports about the company. In a report published on April 4th, TD Cowen raised their price target on Takeda Pharmaceutical to $30 and gave it an 'outperform rating'. In a report published on Thursday, 16th March, Bank of America upgraded the shares of Takeda Pharmaceutical to a "buy" rating from a "neutral" rating. The company's target price was set at $20.00. Four analysts have given the company a buy rating, while one has rated it as a hold. According to MarketBeat the stock currently has an average rating 'Moderate buy' with an average price target of $24.67.
Takeda Pharmaceutical Co. Ltd. is engaged in pharmaceutical drug research and development, manufacturing, export and import sales, and marketing. It is divided into three segments: Prescription drug, Consumer Healthcare and Other. Prescription Drugs includes manufacturing and selling pharmaceutical products.
MarketBeat.com offers a FREE daily email newsletter